Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
Abbott, abnormal, accurately, ACO, adhere, adjacent, admission, admitting, Aircoat, AJCA, alia, angiotesin, antiviral, APP, arrive, art, article, artificially, Asian, aspect, attached, AVALIDE, bankruptcy, barring, baseline, biennial, bladder, blood, bottom, calendar, candidate, captionRichard, Carlo, Cartwright, cessation, Chapter, Chemistry, CHOICE, cited, Civ, clarification, clarifying, Clayworth, Clerk, CMS, collateral, Commonwealth, conditionally, conference, conferring, contraceptive, Cook, coordinate, coordinated, coordination, correctly, Corrupt, COSO, counterpart, covenant, crystalline, Czech, defaulting, demurrer, detect, detection, diligent, disagree, disoproxil, dispensed, dissolution, DOJ, dovetail, durability, Dwyer, ear, Egypt, eighty, EMSAM, emtricitabine, endorsed, enrichment, entirety, enumerated, EPA, EPS, escalate, Estonia, ESTRADIOL, estrogen, Evansville, expertise, explore, Fabre, faith, fare, feature, firm, fourteen, Frameworkissued, fraudulently, fruitful, FSP, fumarate, German, Gilead, Glasgow, GLP, Guam, guaranty, HAART, hand, harm, HORMONE, HRT, hundred, Hungary, ideally, idle, immunologic, inadequate, Indiana, induce, inducing, Industriesissued, inInternal, insolvency, install, involuntary, IO, ix, JAMA, JAVLOR, Judge, Kaletra, Kentucky, kilogram, kinase, kind, lag, lamivudine, language, LAP, Latvia, leasehold, lengthen, leukemia, licensure, lift, light, Lithuania, LLC, lump, magnetic, Malta, mammalian, mechanism, Medarex, Medicament, Medicel, melanoma, mild, Minister, misreported, mistakenly, MIT, MMA, monoamine, motor, movement, MRI, Munich, Municipality, murgalitazar, Mylan, naive, neighboring, newer, ninety, NNRTI, NOA, nonexclusive, nonmonetary, Notaristefani, novelty, Novopharm, NRD, nullity, occurrence, OCI, ODS, offshore, OIG, opportunity, optimal, outmovement, overpayment, oxidase, Pakistan, patch, Patti, payout, payroll, peer, penalty, permanently, peroxisome, PhRMA, Pierre, Pilot, placebo, played, playing, pled, Poland, polymorph, pool, preempted, prejudice, preliminarily, Premarin, Prempro, priority, progestin, proliferator, prompt, proof, propounded, prosecution, prosecutor, psychotic, question, radiopharmacy, Ranbaxy, ranked, recalculated, recalculation, recasting, reconfirm, reconfirmed, recur, reexam, reexamination, refocused, refrigeration, reinstated, render, repair, repeated, replead, representation, Republic, requisite, Reseller, resonance, retroactive, revert, revoked, RNA, role, Saxagliptin, sBLA, Scotland, sector, segregated, selegiline, Senate, Session, shelf, SHS, sicor, simplify, situation, sixteen, sixty, Slovakia, Slovenia, solicit, solicitation, Solvay, Somerset, sooner, Southeast, Staatsanwaltin, standstill, steadily, Steering, Stockand, stopped, sublicense, substance, substantive, suspended, Swanston, Syracuse, TAXOL®in, tenofovir, theAmerican, therefrom, theTax, throat, tight, toddler, top, toxicity, toxicology, transcriptase, transdermal, translated, translating, translation, transriptase, Treadway, tribal, TRUVADA, UK, unaffiliated, unamortized, unauthorized, unbranded, uncured, undergoing, undergone, unilaterally, unjust, unresectable, unsolicited, unstayed, uphold, USPTO, vaccine, Ventiv, vinflunine, vital, waive, warehouse, Watson, Wisconsin, wrong, wrongdoing, Wyeth, xi, xii, Zito
Filing tables
Filing exhibits
- 10-K Annual report
- 3 Bylaws of Bristol-myers Squibb Company, As Amended As of January 3, 2005
- 4 Five Year Competitive Advance and Revolving Credit Facility Agreement
- 10 Bristol-myers Squibb Company 1983 Stock Option Plan
- 10 Bristol-myers Squibb Company 1987 Deferred Compensation Plan
- 10 Form of Agreement Entered into Between Bristol-myers Squibb Company
- 12 Statement Re Computation of Ratios
- 21 Subsidiaries of the Registrant
- 23 Consent of Pricewaterhousecoopers
- 31 Section 302 Certification Letter
- 31 Section 302 Certification Letter
- 32 Section 906 Certification Letter
- 32 Section 906 Certification Letter
Related press release
BMY similar filings
Filing view
External links
EXHIBIT 12.
Statement Re Computation of Ratios
2004 | 2003 | 2002 | 2001 | 2000 | ||||||||||||||||
(dollars in millions) | ||||||||||||||||||||
5-Year Ratio of Earnings to Fixed Charges: | ||||||||||||||||||||
Earnings | ||||||||||||||||||||
Earnings from Continuing Operations Before Minority Interest and Income Taxes | $ | 4,418 | $ | 4,680 | $ | 2,748 | $ | 2,252 | $ | 5,244 | ||||||||||
Fixed Charges | 369 | 361 | 420 | 233 | 148 | |||||||||||||||
Capitalized interest, net of amortization | (10 | ) | (35 | ) | (16 | ) | (16 | ) | (12 | ) | ||||||||||
Total Earnings | $ | 4,777 | $ | 5,006 | $ | 3,152 | $ | 2,469 | $ | 5,380 | ||||||||||
Fixed Charges | ||||||||||||||||||||
Interest and debt expense | $ | 310 | $ | 277 | $ | 364 | $ | 182 | $ | 108 | ||||||||||
Capitalized interest | 10 | 35 | 16 | 16 | 12 | |||||||||||||||
One-third of rental expense | 49 | 49 | 40 | 35 | 28 | |||||||||||||||
Total Fixed Charges | $ | 369 | $ | 361 | $ | 420 | $ | 233 | $ | 148 | ||||||||||
Ratio of Earnings to Fixed Charges | 12.95 | 13.87 | 7.50 | 10.60 | 36.35 |
E-12-1